The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.

Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral ...

Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors to expand its anticoagulation ...

The deal marks the second time Novartis has tapped Monte Rosa’s services in just under year. The US big pharma company paid ...

US-based Amneal Pharmaceuticals has secured approval from the FDA for its 500mg/mL sodium oxybate oral solution.

AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, according to reports from ...

FDA chief Martin Makary said the agency will now ‘proactively monitor’ pharma companies for advertising law breaches.

LB Pharmaceuticals’ public listing comes amid a dry spell for biotech IPOs despite a flurry of activity early in 2025.

On this episode, the healthcare editorial team unpicks several key trials and trends from this year’s event, held from 29 ...

AbbVie has struck deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.